Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Change in Cash (2020 - 2025)

Historic Change in Cash for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$7.8 million.

  • Ovid Therapeutics' Change in Cash rose 4682.84% to -$7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 11318.78%. This contributed to the annual value of -$740000.0 for FY2024, which is 9584.88% up from last year.
  • Per Ovid Therapeutics' latest filing, its Change in Cash stood at -$7.8 million for Q3 2025, which was up 4682.84% from $7.3 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Change in Cash peaked at $161.0 million during Q1 2021, and registered a low of -$93.9 million during Q2 2022.
  • In the last 5 years, Ovid Therapeutics' Change in Cash had a median value of -$10.4 million in 2021 and averaged -$2.6 million.
  • As far as peak fluctuations go, Ovid Therapeutics' Change in Cash skyrocketed by 120586.73% in 2021, and later crashed by 34940.43% in 2022.
  • Ovid Therapeutics' Change in Cash (Quarter) stood at -$12.1 million in 2021, then fell by 11.1% to -$13.4 million in 2022, then crashed by 127.01% to -$30.4 million in 2023, then surged by 137.13% to $11.3 million in 2024, then crashed by 169.16% to -$7.8 million in 2025.
  • Its Change in Cash stands at -$7.8 million for Q3 2025, versus $7.3 million for Q2 2025 and -$5.2 million for Q1 2025.